Effect of pravastatin on blood pressure in people with cardiovascular disease

Journal of Human Hypertension
M TonelliG Curhan

Abstract

Experimental evidence and several small studies in humans suggest that HMG-CoA (3-hydroxy 3-methylglutaryl coenzyme A) reductase inhibitors (statins) reduce blood pressure, perhaps through effects on endothelial function or by reducing inflammation. We tested the hypothesis that pravastatin would reduce blood pressure at 3 months and the risk of developing new hypertension over a follow-up period of 5 years. This was a post hoc subgroup analysis of a randomized double-blind placebo-controlled trial of pravastatin 40 mg daily vs placebo in 4159 participants with previous myocardial infarction and total plasma cholesterol <240 mg/dl (6.2 mmol/l). The primary outcome was the unadjusted change in mean arterial pressure (MAP) from baseline to 3 months. We also considered systolic and diastolic blood pressure (SBP and DBP) and pulse pressure. Analysis of covariance was used to calculate the adjusted effect of treatment on change in these outcomes at 3, 6, 12 and 24 months postrandomization, after controlling for potential confounders. Logistic regression was used to calculate the adjusted effect of treatment on incident hypertension (blood pressure > or =140/90 in those without known hypertension at baseline). This analysis included ...Continue Reading

References

Feb 11, 1995·Lancet·G K GoodeA M Heagerty
Apr 25, 2000·Journal of Cardiovascular Pharmacology·C BorghiE Ambrosioni
Dec 15, 2000·European Journal of Clinical Investigation·G TonoloM Maioli
Jul 4, 2001·JAMA : the Journal of the American Medical Association·M A AlbertUNKNOWN PRINCE Investigators
Mar 19, 2002·Journal of the American College of Cardiology·Kathryn E FerrierBronwyn A Kingwell
Apr 2, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Bertram L Kasiske
Nov 22, 2002·Journal of Human Hypertension·A S Wierzbicki
Dec 11, 2002·Kidney International·G V Ramesh PrasadJeffrey S Zaltzman
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Sebastian WolfrumJames K Liao
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Sep 19, 2003·Journal of the American College of Cardiology·Dinko SusicEdward D Frohlich
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Howard D SessoPaul M Ridker
Aug 17, 2004·American Heart Journal·Claudio BorghiUNKNOWN Brisighella Heart Study Working Party
Sep 14, 2004·Journal of Human Hypertension·A IchiharaT Saruta

❮ Previous
Next ❯

Citations

Jan 9, 2007·Cardiovascular and Interventional Radiology·Anthony S Wierzbicki
Nov 26, 2010·Clinical and Experimental Hypertension : CHE·Jian-Jun LiUNKNOWN Chinese Coronary Secondary Prevention Study (CCSPS) Group
May 20, 2008·Thrombosis Research·Eduard ShantsilaGregory Y H Lip
Jun 2, 2007·The Journal of Clinical Hypertension·Pantelis A SarafidisAnastasios N Lasaridis
Apr 26, 2013·The Journal of Clinical Hypertension·Alexandros BriasoulisFranz H Messerli
Apr 23, 2013·International Journal of Cardiology·Maciej BanachUNKNOWN Lipid and Blood Pressure Meta-Analysis Collaboration Group
Jul 1, 2011·Journal of Cardiovascular Disease Research·Manuel MorgadoMiguel Castelo-Branco
Jul 20, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Adrian DrapalaMarcin Ufnal
Jul 27, 2012·American Journal of Hypertension·Luis I JuncosNestor H García
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.